Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M83,617Revenue (TTM) $M24,062Net Margin (%)9.1Altman Z-Score1.7
Enterprise Value $M95,919EPS (TTM) $0.9Operating Margin %14.8Piotroski F-Score7
P/E(ttm)43.0Beneish M-Score-2.5Pre-tax Margin (%)9.9Higher ROA y-yY
Price/Book6.710-y EBITDA Growth Rate %4.9Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-16.1Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow74.1y-y EBITDA Growth Rate %16.1ROA % (ttm)3.7Higher Current Ratio y-yY
Dividend Yield %4.2PEG--ROE % (ttm)13.5Less Shares Outstanding y-yY
Payout Ratio %160Shares Outstanding M2,530ROIC % (ttm)12.4Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDodge & Cox 2016-06-30 Add0.19%$27.26 - $30.25
($29.03)
$ 33.8217%Add 24.89%32,532,723
AZNNWQ Managers 2016-06-30 Add0.03%$27.26 - $30.25
($29.03)
$ 33.8217%Add 13.06%572,985
AZNDavid Dreman 2016-06-30 Buy 0.02%$27.26 - $30.25
($29.03)
$ 33.8217%New holding1,321
AZNKen Fisher 2016-06-30 Add0.01%$27.26 - $30.25
($29.03)
$ 33.8217%Add 45.23%338,979
AZNDodge & Cox 2016-03-31 Add0.39%$27.95 - $33.95
($30.11)
$ 33.8212%Add 121.19%26,049,650
AZNNWQ Managers 2016-03-31 Reduce$27.95 - $33.95
($30.11)
$ 33.8212%Reduce -1.83%506,785
AZNKen Fisher 2016-03-31 Add$27.95 - $33.95
($30.11)
$ 33.8212%Add 5.33%233,409
AZNDodge & Cox 2015-12-31 Buy 0.39%$30.47 - $34.77
($32.84)
$ 33.823%New holding11,777,132
AZNNWQ Managers 2015-12-31 Add0.01%$30.47 - $34.77
($32.84)
$ 33.823%Add 5.24%516,215
AZNKen Fisher 2015-12-31 Add0.01%$30.47 - $34.77
($32.8)
$ 33.823%Add 692.95%221,606
AZNNWQ Managers 2015-09-30 Add0.09%$30.28 - $34.54
($32.89)
$ 33.823%Add 60.04%490,535
AZNMario Gabelli 2015-09-30 Sold Out $30.28 - $34.54
($32.89)
$ 33.823%Sold Out0
AZNKen Fisher 2015-09-30 Buy $30.28 - $34.54
($32.89)
$ 33.823%New holding27,947
AZNDavid Dreman 2015-06-30 Sold Out -0.16%$31.86 - $36.68
($34.24)
$ 33.82-1%Sold Out0
AZNNWQ Managers 2015-06-30 Add0.12%$31.86 - $36.68
($34.24)
$ 33.82-1%Add 486.45%306,510
AZNMario Gabelli 2015-06-30 Reduce$31.86 - $36.68
($34.24)
$ 33.82-1%Reduce -28.81%8,400
AZNDavid Dreman 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.74)
$ 33.82-3%Reduce -4.43%54,978
AZNNWQ Managers 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.74)
$ 33.82-3%Reduce -21.34%104,530
AZNMario Gabelli 2015-03-31 Reduce$32.22 - $36.35
($34.74)
$ 33.82-3%Reduce -40.70%23,600
AZNDavid Dreman 2014-12-31 Reduce-0.51%$33.58 - $37.69
($35.81)
$ 33.82-6%Reduce -75.42%57,528
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1798.94view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
    Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
    Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
    Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
    Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
    Vanguard Adds to Four of Its Largest Stakes May 04 2015 

    More From Other Websites
    22 September 2016 Liquid biopsy: plasma ctDNA testing moves into mainstream cancer treatment Sep 29 2016
    7:03 am AstraZeneca announces that the FDA has approved a blood-based companion diagnostic for... Sep 29 2016
    US FDA Approves TAGRISSO® (osimertinib) Blood-Based T790M Companion Diagnostic Test Sep 29 2016
    These two FTSE 100 dividends stars still look cheap Sep 29 2016
    Big Pharma takes big lease in South S.F. to consolidate California operations Sep 28 2016
    Zuckerberg initiative poaches AstraZeneca board member Sep 28 2016
    Zuckerberg initiative poaches AstraZeneca board member Sep 28 2016
    Zuckerberg initiative poaches AstraZeneca board member Sep 28 2016
    28 September 2016 Professor David Goldstein to lead AstraZeneca’s genomics initiative as Chief... Sep 28 2016
    Do these 3 low yielders offer high growth prospects? Sep 27 2016
    Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy Sep 27 2016
    Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema Sep 26 2016
    Unexpected Twist: Pfizer Scraps Breakup Following Dead Allergen Merger Sep 26 2016
    vTv Therapeutics Shares Initiated With Buy Rating, $13 Target Sep 26 2016
    Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO Sep 23 2016
    Coverage initiated on AstraZeneca by Piper Jaffray Sep 23 2016
    Is this a better healthcare buy than AstraZeneca plc after today’s update? Sep 23 2016
    23 September 2016 Innovative pancreatic research expands treatment horizons for people with type 2... Sep 23 2016
    AstraZeneca Withdraws Cediranib Marketing Application in EU Sep 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)